All In Biotech

Drug Trial Radar · NCT04176380

RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma

Phase II Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of Relapsed, Refractory Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15

Actual

Start

Dec 2, 2020

Primary completion

Jan 30, 2023

Study completion Jun 6, 2023

Sponsor

Lead sponsor
Rapa Therapeutics LLCIndustry
Sponsor type
Industry
Collaborators
Medical College of Wisconsin
First posted
Nov 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at least three (3) prior lines.

Conditions

  • Relapsed, Refractory Multiple Myeloma

Interventions

  • RAPA-201 Autologous T cellsBiological

    Autologous rapamycin resistant Th1/Tc1 cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rateTime frame: One (1) year after last dose of RAPA-201 cells.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.